Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
TENOFOVIR DISOPROXIL 26,978 1,235 4.6% 3,617 216 48.2 yrs 31.8%
LAMIVUDINE 16,685 1,838 11.0% 3,442 423 43.0 yrs 35.2%
ZIDOVUDINE 6,722 816 12.1% 1,067 203 30.4 yrs 48.1%
ABACAVIR 4,282 524 12.2% 890 160 41.7 yrs 41.3%
EMTRICITABINE 3,718 499 13.4% 797 87 42.2 yrs 41.9%
TENOFOVIR ALAFENAMIDE 2,990 311 10.4% 713 38 58.6 yrs 39.3%

Head-to-Head Comparisons

TENOFOVIR DISOPROXIL vs LAMIVUDINE TENOFOVIR DISOPROXIL vs ZIDOVUDINE TENOFOVIR DISOPROXIL vs ABACAVIR TENOFOVIR DISOPROXIL vs EMTRICITABINE LAMIVUDINE vs ZIDOVUDINE LAMIVUDINE vs ABACAVIR LAMIVUDINE vs EMTRICITABINE ZIDOVUDINE vs ABACAVIR ZIDOVUDINE vs EMTRICITABINE ABACAVIR vs EMTRICITABINE
← Back to Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Class side effects →